Scarica l'app Stockscreener
2.11
0.00%
0.00
Pre-mercato:
2.12
0.01
+0.47%
Cervomed Inc Borsa (CRVO) Ultime notizie
CervoMed Inc. (NASDAQ:CRVO) Receives $42.00 Average Price Target from Analysts - Defense World
AWM Investment Company, Inc. Reduces Stake in CervoMed Inc - GuruFocus.com
CervoMed (STU:DP8) Momentum Rank : 8 (As of Jan. 11, 2025) - GuruFocus.com
Geode Capital Management LLC Raises Holdings in CervoMed Inc. (NASDAQ:CRVO) - Defense World
Barclays PLC Acquires 5,919 Shares of CervoMed Inc. (NASDAQ:CRVO) - Defense World
Brookline Capital Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN
State Street Corp Boosts Stake in CervoMed Inc. (NASDAQ:CRVO) - Defense World
Analysts Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $42.00 - Defense World
HC Wainwright Brokers Reduce Earnings Estimates for CervoMed - Defense World
HC Wainwright & Co. Downgrades CervoMed (CRVO) - MSN
Research Analysts Issue Forecasts for CervoMed Q1 Earnings - Defense World
CervoMed (NASDAQ:CRVO) Cut to Hold at Brookline Capital Management - Defense World
CervoMed price target lowered to $4 from $45 at Roth MKM - Yahoo Finance
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CervoMed Awards Key Executive Stock Options in Strategic Talent Acquisition Move - StockTitan
CervoMed's dementia drug fails mid-stage trial, shares slump - MSN
Chardan Capital Downgrades CervoMed (CRVO) - MSN
What Was Behind CervoMed’s Lewy Body Disappointment? - News & Insights
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint - Yahoo Finance
Morgan Stanley cuts CervoMed to Underweight on disappointing trial results By Investing.com - Investing.com UK
CervoMed stock downgraded to Hold as Phase 2b trial disappoints By Investing.com - Investing.com Canada
CervoMed shares rating downgraded after trial data disappoints - Investing.com
Jones Trading Downgrades CervoMed (CRVO) - MSN
CervoMed's dementia drug fails to meet mid-stage trial goals - MSN
CervoMed stock downgraded to Hold as Phase 2b trial disappoints - Investing.com
CervoMed shares rating downgraded after trial data disappoints By Investing.com - Investing.com Canada
CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease - MSN
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets - Yahoo Finance
US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift' - Benzinga
CervoMed Shares Slide to All-Time Low After Study Failure - MarketWatch
CervoMed’s dementia drug fails to meet mid-stage trial goals - 1470 & 100.3 WMBD
Late-stage plans on ice as CervoMed's oral drug fails dementia study - FirstWord Pharma
CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial - Fierce Biotech
CervoMed Inc. Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies - Marketscreener.com
CervoMed tumbles after dementia drug fails to meet mid-stage trial goals - XM
CervoMed Faces Setback in Phase 2b Trial - TipRanks
CervoMed Phase 2b Study of Neflamapimod Misses Main Endpoints - MarketWatch
CervoMed Announces Topline Data from RewinD-LB Phase 2b - GlobeNewswire
HC Wainwright Predicts CervoMed FY2024 Earnings - MarketBeat
CervoMed (NASDAQ:CRVO) Research Coverage Started at HC Wainwright - Defense World
CervoMed (NASDAQ:CRVO) Coverage Initiated at Roth Mkm - Defense World
Research Analysts Set Expectations for CervoMed Q4 Earnings - Defense World
Roth/MKM sets stock target on CervoMed, buy rating on strong trial results - Investing.com Nigeria
HC Wainwright & Co. Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN
CervoMed (NASDAQ:CRVO) Coverage Initiated by Analysts at Roth Mkm - MarketBeat
What is HC Wainwright's Estimate for CervoMed Q4 Earnings? - MarketBeat
Roth MKM Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN
CervoMed Enhances Transparency with Key Information Access - TipRanks
CervoMed (NASDAQ:CRVO) Given “Buy” Rating at D. Boral Capital - Defense World
Morgan Stanley Initiates Coverage of CervoMed (CRVO) with Overweight Recommendation - MSN
FDA grants Orphan Drug status to CervoMed's dementia drug By Investing.com - Investing.com South Africa
CervoMed’s stock rises as FDA grants orphan drug status to dementia drug - Pharmaceutical Technology
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):